Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
7
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
medicare
7
×
national
national blog main
national top stories
7
×
new york blog main
7
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
novartis
alzheimer's disease
cancer
cancer immunotherapy
deals
eli lilly
gene therapy
pfizer
startups
abbvie
amgen
What
bio
roundup
drug
price
alzheimer’s
companies
crispr
gene
new
patients
prices
remains
talk
acquisitions
administration
albert
allogene
angry
annual
anti
approval
assessed
attention
becker
benefited
biggest
billions
biogen’s
biopharmaceutical
biotech
bourla
cancer
ceo
communities
company
conference
convo
despite
different
diversity
Language
unknown
Current search:
biogen
×
" national top stories "
×
medicare
×
" new york blog main "
×
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More